In this study, we aimed to investigate whether MK2 inhibition could result in attenuation of glioblastoma cell proliferation and whether allosteric MK2 inhibitors, such as CMPD1, could be used as new leads for development of glioblastoma treatments. The gene discussed is SOX9; the disease is glioblastoma.